CCND1 and plasma cell myeloma: Interestingly, during the preparation of this manuscript we identified an additional BRAF mutant NMZL case in consultation: a CD45+/CD138+/MUM1+/CD19−/CD20−/CD56−/CD79a−/Cyclin D1− plasmacytoid tumor without myeloma-characteristic translocations and polysomies that was BRAF V600E+ by immunohistochemistry and displayed the V600E mutation by HTS (data not shown).